Research evaluation to study individuals who show thromboxane or P2Y12 receptor resistance

Trial Profile

Research evaluation to study individuals who show thromboxane or P2Y12 receptor resistance

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Eptifibatide; Heparin
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2013 Planned number of patients changed from 600 to 1200 as reported by ClinicalTrials.gov.
    • 19 Jul 2007 Status changed from recruiting to discontinued. Sponsor support withdrawn.
    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top